University of Texas, Southwestern Medical center
Endocrinology
Dr. Philip Raskin, MD
|
|
Give Review
Philip Raskin is an expert in the field of Endocrinology. He attended University of Pittsburgh School of Medicine. He over the years received 10 awards: "CMS Meaningful Use Stage 1 Certification", "The Best Doctors in America Award", "Alumni Award for Achievement", "J. Denis McGarry Award", "Listed in The Best Doctors in America", "Elected Member", "Super Doctor", "Alpha Omega Alpha", "Owens Fellowship" and "Fellow (FACE)". Philip Raskin is a published doctor as well. He has 71 publications published. The latest was: The effect of adding insulin degludec in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled tri... Philip Raskin accepts all Medicare patients.
Publications
- Consensus statement by the american association of clinical endocrinologists/american college of endocrinology insulin pump management task force.
- Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial.
- Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-Up One Year After Cessation of Treatment.
- Targeting of memory T cells with alefacept in new-onset type 1 Diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
- A novel glucose-insulin infusion maintains perioperative glycaemic control through multiple transitions of care.
- B-Lymphocyte Depletion With Rituximab and Beta-Cell Function: Two-Year Results.
- Haptoglobin genotype and the rate of renal function decline in the Diabetes control and complications trial/epidemiology of Diabetes interventions and complications st...
- Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 Diabetes mellitus.
- Interleukin-1 antagonism in type 1 Diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
- Iatrogenic hyperinsulinemia in type 1 Diabetes: Its effect on atherogenic risk markers.
- Managing inpatient hyperglycemia in a resource-constrained county hospital: the parkland memorial hospital experience.
- Basal insulin or premix analogue therapy in type 2 Diabetes patients.
- The fatty hearts of patients with Diabetes.
- Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 Diabetes.
- Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
- Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 Diabetes.
- Cardiac steatosis in Diabetes mellitus: a 1H-magnetic resonance spectroscopy study.
- Insulin-based versus triple oral therapy for newly diagnosed type 2 Diabetes: which is better?
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 Diabetes: a randomized, parallel-group, 24-week study.
- Insulin as initial therapy in type 2 Diabetes: effective, safe, and well accepted.
- Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 Diabetes.
- Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 Diabetes.
- Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 Diabetes mellitus.
- The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and Diabetes.
- Immune-mediated disease and secondary failure to oral therapy in type 2 Diabetes mellitus.
- Improved glycemic control without weight gain using triple therapy in type 2 Diabetes.
- Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
- Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 Diabetes mellitus.
- Oral insulin therapy to prevent progression of immune-mediated (type 1) Diabetes.
- Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 Diabetes.
- Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 Diabetes (LEAD-...
- Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 Diabetes.
- Combination therapy using metformin or thiazolidinediones and insulin in the treatment of Diabetes mellitus.
- Anthropometric features and cardiovascular risk in young Latin Americans with type 2 Diabetes mellitus.
- Hepatitis C infection and Diabetes.
- The relationship between immune-mediated Type 1 Diabetes mellitus and ethnicity.
- The effect of rosiglitazone on overweight subjects with type 1 Diabetes.
- Comparison of type 1, type 2, and atypical ketosis-prone Diabetes at 4 years of Diabetes duration.
- Novel insulin analogues and its mitogenic potential.
- Reversible acute renal failure and nephrotic syndrome in a Type 1 diabetic patient.
- Anemia associated with new-onset Diabetes: improvement with blood glucose control.
- The treatment of hypertension in adult patients with Diabetes.
- Blood pressure control--effects on Diabetic nephropathy progression: how low does blood pressure have to be?
- Intractable vomiting in Diabetic patients.
- Diabetic ketoacidosis in type 1 and type 2 Diabetes mellitus: clinical and biochemical differences.
- Vascular effects of rapid-acting insulin analogs in the Diabetic patient: a review.
- Efficacy and safety of insulin detemir.
- Emerging treatments for the prevention of type 1 Diabetes.
- A Stepwise Approach to Insulin Therapy in Patients with Type 2 Diabetes Failing Basal Insulin Treatment.
- A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 Diabetes mellitus inadequately controlled on basal ins...
- Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in Diabetic nephropathy.
- Initiation of insulin therapy in patients with type 2 Diabetes failing oral therapy: response to Mikhail and Cope and to Janka.
- Starting patients with type 2 Diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in...
- Examining correlates of treatment satisfaction for injectable insulin in type 2 Diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues.
- Efficacy of biphasic insulin aspart in patients with type 2 Diabetes.
- Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 Diabetes and hypertension in the Gl...
- Lung function changes related to Diabetes mellitus.
- Can glycemic targets be achieved-- in particular With two daily injections of a mix of intermediate- and short-acting insulin?
- The Diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin.
- Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 Diabetes.
- A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 Diabetes.
- Effects of multiple daily insulin injections on peripheral glucose disposal in Latin Americans with type 2 Diabetes mellitus.
- The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 Diabetes.
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 Diabetes: a randomised double-blind trial.
- Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 Diabetes: results from ...
- Differential effects of beta-blockers on albuminuria in patients with type 2 Diabetes.
- Metabolic effects of carvedilol vs metoprolol in patients with type 2 Diabetes mellitus and hypertension: a randomized controlled trial.
- Exenatide extended-release: a once weekly treatment for patients with type 2 Diabetes.
- Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial.
- The effect of adding insulin degludec in patients with type 2 Diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled tri...
Schools
University of Pittsburgh Main Campus
Health Center Hosps University Pittsbur
Southwestern Med School
Conditions Treated
- Acromegaly and Gigantism
- Adrenal Insufficiency
- Calcium Metabolism Disorders
- Diabetes Mellitus, Secondary
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Assurant Health
- Blue Card PPO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Preferred PPO
- Medicare MCR
- Molina
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- The Best Doctors in America Award
- Alumni Award for Achievement
- J. Denis McGarry Award
- Listed in The Best Doctors in America
- Elected Member
- Super Doctor
- Alpha Omega Alpha
- Owens Fellowship
- Fellow (FACE)
Education
-
University of Pittsburgh Medical Center -
University of Pittsburgh School of Medicine
Hospital
-
University of Texas Southwestern Medical Center
Drug Facts
| NPI NUMBER | 1528024098 | |
| NPPES Provider LastName | RASKIN | |
| NPPES Provider FirstName | PHILIP | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 1168.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528024098 |
| Last Name Of The Provider | RASKIN |
| First Name Of The Provider | PHILIP |
| View All |
Similar Doctors
|
Dr. Magdalene M. Szuszkiewicz-Garcia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin D. Roe, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jaime P. Almandoz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard E. Berger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven G. Dorfman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sasan Mirfakhraee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steve V. Fordan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean D. Wilson, MD
This Doctor is OpenDoctor Recommended.
|